Abemaciclib
Verzenio, Verzenios (abemaciclib) is a small molecule pharmaceutical. Abemaciclib was first approved as Verzenio on 2017-09-28. It has been approved in Europe to treat breast neoplasms. It is known to target cyclin-dependent kinase 6 and cyclin-dependent kinase 4. Verzenio's patent is valid until 2029-12-15 (FDA).
| Trade Name | Verzenios |
|---|---|
| Common Name | Abemaciclib |
| Indication | breast neoplasms |
| Drug Class | Cyclin dependent kinase inhibitors |
